Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company VaxGen has filed against the US government for the termination of a contract to supply an anthrax vaccine to the national stockpile.
Subscribe to our email newsletter
The company, which specializes in the prevention and treatment of infectious diseases, has filed a notice of appeal at the Civilian Board of Contract Appeals regarding the contract cancellation. VaxGen said that the filing was made in anticipation of the approaching appeal deadline of March 19.
Californian-based VaxGen added that the filing preserves its right to challenge the default termination while the company continues to discuss with the Department of Health and Human Services a possible settlement of the contract termination and related issues as an alternative to the pending litigation.